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In different tumour entities, expression of the chemokine receptor 4 (CXCR4) has been linked to tumour dissemination and poor
prognosis. Therefore, we evaluated, if the expression of CXCR4 exerts similar effects in human hepatocellular carcinoma (HCC).
Expression analysis and functional assays were performed in vitro to elucidate the impact of CXCL12 on human hepatoma cells lines.
In addition, expression of CXCR4 was evaluated in 39 patients with HCC semiquantitatively and correlated with both, tumour and
patients characteristics. Human HCC and hepatoma cell lines displayed variable intensities of CXCR4 expression. Loss of p53
function did not impact on CXCR4 expression. Exposure to CXCL12 mediated a perinuclear translocation of CXCR4 in Huh7/
Hep3B cells and increased the invasive potential of Huh7 cells. In HCC patients, CXCR4 expression significantly correlated with
progressed local tumours (T-status; P¼0.006), lymphatic metastasis (N-status; P¼0.005) and distant dissemination (M-status;
P¼0.009), as well as with a decreased 3-year-survival rate (P¼0.01). In summary, strong expression of CXCR4 is significantly
associated with progressed hepatocellular cancer.
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Hepatocellular carcinoma (HCC) ranges among the most frequent
cancer entities worldwide with an incidence of more than 500000
cases per year and raising incidence rates in Western countries
(Parkin et al, 2001). While mortality rates of many cancer entities
are decreasing, hepatocellular cancer revealed an significant
increase of death rates during the 1990s (Wingo et al, 2003).
HCC is associated with liver cirrhosis commonly resulting from
inflammatory liver disease, such as chronic hepatitis B (HBV),
hepatitis C (HCV) and to a lesser extent from autoimmune-
triggered hepatitis or cholangitis (AIH, PBC, PSC), but also from
nonviral diseases, such as chronic alcohol intake or exposure to
mycotoxin and aflatoxin B1 (Bosch et al, 1999). Hepatocarcino-
genesis is considered a slow process in which diverse genomic
alterations accumulate, altering the phenotype of hepatocytes and
hence leading to multiple monoclonal and dysplastic hepatocyte
populations (Thorgeirsson and Grisham, 2002). As progress of
dysplastic hepatocytes to HCC might occur simultaneously in
different foci or nodules, variable genomic alterations can be
found within the same liver indicating a genetic heterogeneity of
lesions (Feitelson et al, 2002). Molecular determinants including
mutations and loss of heterozygosity (LOH) in certain tumour-
suppressor genes (i.e. p53, IGF2R, RB1, PTEN) and oncogenes (i.e.
N-ras, E2F4) have recently been proposed and summarised in the
pathway of molecular pathogenesis of human HCC (Feitelson et al,
2002; Thorgeirsson and Grisham, 2002). Nonetheless, it seems very
likely that additional pathogenic alterations instrumentally med-
iate the progression and dissemination of human HCC.
Tumour growth and metastatic dissemination are deemed to
result from an intricate, dysregulated molecular machinery leading
to diverse phenomena in tumour cells, such as resistance to the
induction of apoptosis, immune escape mechanisms as well as
invasion and migration capabilities. Recent data suggest that
chemokine receptors may direct lymphatic and hematogenous
spreading and may furthermore influence the sites of metastatic
growth of different tumours (Arya et al, 2003).
Chemokines and their G-protein-coupled receptors were
originally reported to mediate different pro- and anti-inflamma-
tory responses (Zlotnik and Yoshie, 2000). The chemokine
receptor 4 (CXCR4) was described to regulate the homing of
lymphocytes in inflammatory tissues (Murdoch, 2000). Its natural
ligand, CXCL12 (stromal cell-derived factor 1 alpha (SDF-1a)), is
highly expressed by endothelial cells and in tissues of metastatic
growth, such as lung, liver and lymph nodes, and attracts
lymphocytes into these organs (Phillips et al, 2003). Increased
CXCL12 production by biliary epithelial cells and proliferating bile
ductules in diverse inflammatory liver diseases might play an
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sadditional role in the recruitment of CXCR4-positive inflammatory
cells into the inflamed livers (Terada et al, 2003). Further data
indicate that CXCR4 may be involved in the retention of
alloactivated lymphocytes at sites of graft damage after liver
transplantation (Goddard et al, 2001). Most recently, CXCR4 has
shifted into focus as it might play an important role in tumour
spreading.
High CXCR4 expression was associated with tumour dis-
semination in colorectal, breast and oral squamous cell carcinoma
(Chen et al, 2003; Uchida et al, 2003; Schimanski et al, 2005).
Supporting data from in vitro and murine in vivo tumour
models underlined the key role of CXCR4 for tumour cell
malignancy, as activation of CXCR4 induced migration, invasion
and angiogenesis of cancer cells (Mori et al, 2004). Furthermore,
downregulation of CXCR4 in melanoma cells led to decreased
pulmonary metastasis in mice, both in number and size
(Murakami et al, 2002).
However, no data are presently available on the expression of
CXCR4 in human HCC and its impact on disease progression and
prognosis. Therefore, we evaluated the expression of CXCR4 in
hepatoma cell lines and HCC specimens and correlated the results
with the patients’ clinicopathological parameters and survival.
Furthermore, we elucidated the impact CXCL12 exposure on
CXCR4 localisation and on cellular proliferation and invasion, as
well as of p53 function on CXCR4 expression.
MATERIALS AND METHODS
Cell culture
The human hepatoma cell lines Huh-7, Hep3B as well as CXCR4
deficient HepG2 and p53 dominant-negative transfected HepG2
were cultured in DMEM (Invitrogen, Germany) supplemented
with 10% FCS, 100unitsml
 1 penicillin, 100mgml
 1 streptomycin
(Cambrex, Germany) and 1mML -glutamine (Invitrogen, Germany).
P53 Dominant-negative transfected HepG2 were kindly provided
by M Schuler (Third Departement of Internal Medicine, Johannes
Gutenberg University, Mainz, Germany).
Western blot analysis
Huh-7, Hep3B, HepG2 and p53 dominant-negative transfected
HepG2 cells were washed with PBS and lysed in 0.5% NP-40
solution. Of protein 100mg was loaded on an 10% SDS–PAGE gel.
The gel was transferred onto a PVDF membrane following
seperation. The respective proteins were detected with anti-
CXCR-4 (1:500, CIO115, Capralogics, USA; 1:1000 donkey anti-
goat IgG 2nd antibody SC-2020 by Santa Cruz Biotechnology, CA,
USA) and antiactin (1:1000, A2066, Sigma, Germany; 1:1000 goat
anti-rabbit IgG 2nd antibody 170–6515 by Biorad, USA) and were
visualised by ECL Western Blotting Analysis System (Amersham
Biosciences, USA).
Translocation assays
Translocation of CXCR4 under CXCL12 exposure was assayed in
Huh-7, Hep3B and HepG2 cells. In brief, cells were seeded on
chamber-slides and treated with CXCL12 (100ngml
 1; Sigma,
Germany) for 0, 2 or 24h. IHC-CXCR4 staining and evaluation was
performed as described below. To prove the observed effects,
Huh7, Hep3B and HT29 cells were grown in chamber slides and
exposed to CXCL12 for 0 or 2h. After washing with PBS, the cells
were fixed in methanol/acetone for 2min. For immunofluores-
cence staining an anti-goat-FITC-conjugated IgG secondary
antibody (F2016, Sigma, Germany) was used. Hoechst 33342
(Molecular Probes, Netherlands) was applied to stain nuclei. The
cells were imaged directly in the chambers using a Zeiss LSM
510UV laser scanning microscope.
FACS analysis
HT29 cells were grown in 12-wells in DMEM (Invitrogen,
Germany) supplemented with 10% FCS, 100unitsml
 1 penicillin,
100mgml
 1 streptomycin (Cambrex, Germany) and 1mM
L-glutamine (Invitrogen, Germany). One day before analysis FCS
concentration was reduced to 1%. During analysis, cells were
treated with CXCL12 for 0 or 2h. After trypsination, cells were
washed three times with PBS, finally solved in 25ml PBS and
blocked with 25ml human fresh frozen plasma for 15min at room
temperature. Hereafter, 2ml of PE-conjugated anti-CXCR4 (Clone
12G5; BD Biosciences, Belgium) were added and incubated for
45min at 371C. Cells were again washed in PBS and finally
analysed in a FACSCalibur (BD Biosciences; Belgium).
Proliferation assays
Cells (Huh-7, Hep3B and HepG2 cells) (5 10
3) were plated in 96-
wells. After seeding, cells were either exposed to CXCL12 (Sigma,
Germany) or the equivalent amount of solvent (0.1% BSA in PBS).
The amount of cells per well was determined daily by luminescence
assay according to the recommendations of the manufacturer
(Celltiter-Glo, Cell Viability assay, Promega, USA). Each condition
was performed in quadruplicates.
Cellular migration/invasion assays
Invasion of Huh-7, Hep3B and HepG2 cells was assayed with the
extracellular matrix covered QCM Chemotaxis 96-well cell inva-
sion assay (8mM pore size; QCM Chemotaxis 96-well cell invasion
assay kit; Chemicon International, USA). In brief, cells were serum
starved for 24h before initiation of the assay. Cells (4 10
4) were
resuspended in serum-free DMEM and added to the upper
chamber. Consecutively, DMEM with 20% FCS and 7100ngml
 1
CXCL12 was added to the lower chamber. Chambers were
incubated for 24h at 371C in a humid atmosphere of 5% CO2.
After incubation, the amount of invaded and migrated cells in the
lower chamber was determined by fluorescence assay performed
according to the recommendations of the manufacturer. Each
condition was performed in quadruplicates.
Tissue samples
Hepatocellular carcinoma tissue samples were obtained from 39
patients undergoing liver biopsy, hemihepatectomy or orthotopic
liver transplantation for HCC at the University of Mainz. The
morphological classification of the carcinomas was conducted
according to World Health Organization (WHO) specifications.
Patients were followed up on a regular basis depending on the
procedure performed.
Immunohistochemical staining
The avidin-biotin-complex method was used to detect the protein
CXCR-4 (anti-CXCR-4, dilution 1:300; Capralogics, USA). For-
malin-fixed and paraffin-embedded tissue were deparaffinised and
subsequently microwaved in EDTA buffer. After preincubation
with hydrogen peroxide, avidin/biotin blocking kit (Vector
Laboratories Inc., USA) and rabbit serum (Vector Laboratories
Inc., USA) the primary antibodies were applied for 1h at room
temperature. After incubation with the secondary antibody (rabbit
anti-goat biotinylated; dilution 1:200, Vector Laboratories Inc.,
USA), the avidin-biotin-complex was added and the enzyme
activity visualised with diaminobenzidine. Counterstaining was
performed with haematoxylin. For negative controls only the
secondary antibody was used. A negative control was performed
for every HCC sample (N¼39). For positive controls formalin-
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sfixed and paraffin-embedded tissue samples of the human spleen
were applied.
Evaluation of immunostaining
Immunostaining was evaluated semiquantitatively by three
authors independently (CCS, RB, NS), blinded to patient outcome
and all clinicopathologic findings. The immunohistochemical
staining was analysed according to a scoring method that we have
previously validated and described (Schimanski et al, 2005): the
tumours were classified into four groups based on the homo-
genous staining intensity: 0, absent; 1, weak; 2, intermediate; 3,
strong staining. In the case of heterogeneous staining within the
same sample, the respective, 0.5 points higher score was chosen, if
more than 50% of cells revealed the higher staining intensity. If the
evaluations did not agree the specimens were re-evaluated and
then classified according to the assessment given most frequently
by the observers.
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Figure 1 (A) Expression and immunohistochemical staining of CXCR4 in diverse human hepatoma cell lines. Huh7 and Hep3B cells revealed a weak
CXCR4 expression, whereas HepG2 cell lines depicted medium CXCR4 staining, independent from p53 status. (B) Exposure to CXCL12 mediated a rapid
perinuclear translocation of CXCR4 from the cytoplasma and membrane (inlet patch). This translocation was strongly evident in Huh7 and also in Hep3B
cells, but absent in HepG2 cells. (C) Fusion of nuclear staining (blue) and CXCR4 staining (green). Exposure to CXCL12 mediated a rapid cytoplasmatic
clearance and perinuclear translocation of CXCR4 in HT29. (D) FACS analysis revealed a significantly decreased amount of positive HT29 cells for
membrane-bound-CXCR4 upon CXCL12 exposure.
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The association of staining intensity with clinicopathological
patterns was assessed with the w
2-test and with the unpaired
Student’s t-test, when appropriate. Survival rates were visualised
applying the Kaplan–Meier curves, and P-values were determined
by the log-rank test. Po0.05 was considered significant and
Po0.001 highly significant in all statistical analyses.
RESULTS
CXCR4 expression in hepatoma cell lines
CXCR4 expression analysis of human hepatoma cell lines revealed
varying expression intensities as depicted by Figure 1A. CXCR4-
immunostaining results correlated with the respective Western
blot analysis (Figure 1A). CXCR4 immunostaining and Western
blot analysis correlated with the respective immunofluorescence
profile (confirmatory results not shown). Notably, p53 did not
impact on CXCR4 expression.
Translocation assays
CXCL12 induced translocation of CXCR4 from the membrane and
cytoplasma to the perinuclear region was present in Huh7 and
Hep3B cells, but absent in CXCR4-defecient HepG2 cell lines,
which were used as a negative control and proof of principle in all
functional assays (Figure 1B). Immunofluorescence analysis
revealed, that exposure to CXCL12 mediated a rapid cytoplasmatic
clearance and translocation of CXCR4 in Huh7 and Hep3B
(confirmatory data not shown) and in HT29 (Figure 1C).
FACS analysis
CXCL12 mediated a rapid decrease of HT29 cells positive for
membrane-bound CXCR4 ( CXCL12: 22.46%; s.d. 6.24; þCXCL12:
5.49%; s.d. 0.38; Po0.01).
Proliferation assays
The chemokine CXCL12 slightly stimulated proliferation of Huh-7
(Luminescence on day 4: 80376887395512 IE vs 71469407586960
IE; P¼0.05), but not of Hep3B (Luminescence on day 4:
27455287147741 IE vs 25330507254525 IE; NS) or HepG2
(Luminescence on day 4: 35170477173299 IE vs
35983287294455 IE; NS) hepatoma cells (Figure 2A).
Migration/invasion assays
The chemokine CXCL12 significantly stimulated migration of
Huh-7 (Fluorescence: 3088073298 IE vs 1570571801 IE; P¼0
.001), but not of Hep3B (Fluorescence: 1436772694 IE vs 158857
1559 IE; NS) or HepG2 (Fluorescence: 76087110 IE vs 79567416
IE; NS) hepatoma cells (Figure 2B).
Tumour characteristics and patient profiles
The selected group of patients represent the typical characteristics
of hepatocellular cancer in industrialised countries, except for a
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Figure 2 (A and B) Exposure to CXCL12-induced proliferation and
invasion of Huh7, but not of Hep3B or HepG2 cells. While the impact of
CXCL12 on invasion was highly significant, it was only marginally significant
on proliferation.
Table 1 Patient and tumour characteristics
Patient characteristics
Total number 39
Median age (years) 60.6
Gender
Female 4 (10%)
Male 35 (90%)
T-status
1 8 (20%)
2 10 (26%)
3 16 (41%)
4 5 (13%)
N-status
0 24 (62%)
1 10 (26%)
2 4 (10%)
Unknown 1 (2%)
M-status
0 26 (67%)
1 12 (31%)
Unknown 1 (2%)
Grading
1 3 (8%)
2 25 (64%)
3 11 (28%)
3-year-survival 54%
CXCR4 expression in hepatocellular cancer
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survival resulting from hemihepatectomy and orthotopic liver
transplantation for HCC. Patients characteristics are depicted in
Table 1.
Immunohistochemical staining of CXCR4 in HCC
The staining for CXCR4 revealed predominantly a cytoplasmatic,
and in few specimens an additional weak membranous or nuclear
location of CXCR4 (Figures 3A–D). The respective expression rate
for CXCR4 was 100% (39 out of 39) and varied from weak (8%),
intermediate (56%) to strong (36%).
Negative controls of human hepatocellular cancer remained
negative for every tissue sample (N¼39, not shown). Splenic
lymphocytes revealed a strong CXCR4 expression matching human
hepatocellular cancer tissue or cell lines with strong expression of
CXCR4. Similarly, inflammatory infiltates of the liver depicted a
strong CXCR4 expression.
Relevance of CXCR4 expression in HCC
Strong CXCR4 expression did correlate with local progression and
proliferation of the primary tumour as indicated by the T-status
(TNM classification; P¼0.006; Table 2), with lymph node
involvement (N-status;P ¼0.005) and with distant metastases
(M-status; P¼0.009; Table 2). Evidently, CXCR4 expression did
not have impact on the grading, medium age or gender.
Concerning survival, a strong CXCR4 expression (grades 2.5 and
3) could not be significantly correlated with survival (P¼0.2).
Noteworthy, if a subgroup with grade 3 expression (homogenous
strong expression) was compared to the rest (heterogenous strong
or lower) a decreased 3-year-survival rate of 25%, as compared to
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Figure 3 (A) Depicts the respective cytoplasmatic expression grades of CXCR4 (weak; medium and strong) as well as a rare sample of a membranous
CXCR4 staining. (B) The probability of survival of HCC patients is given in relation to time after histological confirmation. Patients with grade 3 CXCR4
expression showed a significantly reduced 3-year-survival rate as compared to all other patients (P¼0.01).
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s57% was observed. This difference is depicted in the respective
survival plot (Figure 3B, log rank P¼0.01).
DISCUSSION
So far, no data have been available on the expression of CXCR4 in
human HCC and its impact on disease progression and prognosis.
In other tumour entities, expression of the chemokine receptor
CXCR4 has been linked to tumour dissemination and poor
prognosis. Therefore, we analysed the expression profile of CXCR4
in a series of human hepatoma cell lines and HCC patients. Diverse
external factors, such as hypoxia (hif-1-pathway) and the
activation of adenosine receptors, as well as internal cellular
alterations like the inactivation of tumour-suppressor genes pVHL,
p53 or the overexpression of NFkB have been defined as important
molecular regulators of the CXCR4 expression (Helbig et al, 2003;
Staller et al, 2003; Mehata et al, 2004). To verify the regulation of
CXCR4 by p53 in human HCC, we investigated the CXCR4
expression profile in p53 wt and dominant-negative transfected
HepG2 cells, Huh7 and Hep3B cells (Figure 1A and B). The human
hepatoma cell lines analysed revealed different intensities of a
predominantly cytoplasmatic CXCR4 expression. Interestingly,
the p53 dominant-negative HepG2 cells revealed unchanged levels
of CXCR4 expression as compared to wt HepG2 cells, failing to
confirm a regulatory mechanism of p53 on CXCR4 expression in
transformed hepatic cells, although a p53-mediated impact on
CXCR4 expression has been previously proposed for other cell
lines (Mehata et al, 2004). Exposure to CXCL12, the ligand of
CXCR4, mediated a rapid perinuclear translocation of CXCR4 in
Huh7 and Hep3B, but not in HepG2 cells within two hours,
indicating a cellular activation with pseudopodia formation as
classically observed in epithelial mesenchymal transition (EMT). A
clathrin-mediated endocytosis following activation and perinuc-
lear translocation of CXCR4 to the perinuclear rab4-, rab5- and
rab11-compartment of receptor recycling has previously been
reported in human CD34þ haematopoetic progenitor cells (Zhang
et al, 2004). Unfortunatelly, FACS analysis of CXCR4 in Huh7 and
Hep3B cells previously failed for technical reasons, due to a weak
expression level of CXCR4; HepG2 cells could also not be applied
due to the defect receptor. In order to confirm the observed
translocation in human carcinoma cells we used HT29 cells, which
had previously revealed a strong CXCR4 expression and an intact
CXCR4 receptor (Schimanski et al, 2005). FACS and immuno-
fluorescence analysis confirmed an internalisation of CXCR4 and
a rapid perinuclear translocation upon CXCL12 exposure. In
hepatoma cells, exposure to CXCL12 increased proliferation and
invasion of Huh7, but not of Hep3B or HepG2 cells. While the
impact of CXCL12 on proliferation of Huh7 cells was only
marignal, it was significant on invasion. The observed absence of
CXCR4 translocation and CXCL12 induced proliferation/invasion
in HepG2 cells, confirms earlier data, indicating a loss of
chemokine CXCL12-mediated CXCR4 signalling and receptor
internalisation in HepG2 cells due to a receptor defect (Mitra
et al, 2001). In contrast to HepG2 cells, a defect of the intracellular
signal cascade has to be proposed for Hep3B cells, resulting in a
resistance to CXCL12-mediated phenomena in spite of receptor
translocation. Taken together, our data are in line with in vitro
results from other tumour entities, revealing that CXCR4 is
essential for proliferation, adhesion, migration and invasion of
CXCR4 expressing cancer cells, although the impact of CXCL12 in
Huh7 was dramatically stronger on invasion than on proliferation
(Mori et al, 2004; Schimanski et al, 2005).
The liver, lungs and lymph nodes are major target organs for
metastases of diverse cancers in men. Recent publications on
CXCR4 are in line with the ‘homing’ theory as CXCR4 expression
comediates dissemination of primary tumours to different organs
through the chemotactic factors CXCL12. Homing factors,
influencing chemotaxis to target organs, have been proposed as
the filter function of these organs not solely explains the growth of
metastases (Stetler-Stevenson and Kleiner, 2001). Herein, chemo-
kine CXCL12 expression seems to be most intense in typical
‘homing organs’ such as lungs, bone marrow, liver and lymph
nodes as compared with other nonhoming tissues (Phillips et al,
2003). Furthermore, endothelial cells, such as pulmonary en-
dothelial cells have been shown to coexpress CXCL12 and vascular
cellular adhesion molecule (VCAM)-1, thus mediating tumour-
cell/endothelial-cell attachment (Cardones et al, 2003). In
particular, binding of CXCL12 on CXCR4-induced b-integrin
expression on cancer cells, which was critical to adhesion of
cancer cells to VCAM on endothelial cells (Burger et al, 2003).
In a murine model only CXCR4 expressing, but not CXCR4-
deficient CT-26 colon carcinoma cells grew into macrometastases;
nonetheless both cell types were able to colonise livers and lungs
after injection (Zeelenberg et al, 2003). Interestingly, oval cells,
known to express CXCR4 as well, have been reported to migrate to
the liver along a CXCL12 gradient, established by injured
hepatocytes, inducing oval-cell-aided liver regeneration in hepa-
titis (Hatch et al, 2002; Mavier et al, 2004). Thus, hepatic tumour
dissemination and hepatic regeneration share common pathways
of chemotaxis.
In our experiments, immunohistochemical staining of human
HCC specimens displayed cytoplasmatic CXCR4 expression with
variable intensities, matching the observations made in human
colorectal cancer cell lines. A membranous or nuclear localisation
of CXCR4 was observed in fewer cases, but an inducible
translocation of CXCR4 from the cytoplasma to the membrane
has been reported previously (Richard et al, 2004).
In our patients, a strong CXCR4 expression was significantly
associated with locally progressed tumours, lymph node and
distant metastases. In contrast to other cancer entities, progressed
Table 2 Patient and tumour characteristics dependent on intensity of
CXCR4 expression
CXCR4 expression
Weak (1) Intermediate (2) Strong (3) Statistics
Total number 3 (8%) 22 (56%) 14 (36%)
Average age (years) 61.2 60.4 NS
Gender
Female 2 2 NS
Male 23 12
T-status
1+2 16 2 P¼0.006
3+4 9 12
N-status
a
02 0 4 P¼0.005
+5 9
M-status
a
02 1 5 P¼0.009
+4 8
Grading
1+2 17 11 NS
3+4 8 3
3-year-survival 53% 55% NS
58% 25% P¼0.01
aN and M status could not be obtained from one patient. NS¼not significant.
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the respective hepatocellular cancer. Thus, our results not
necessarily imply a substantial influence of CXCR4 on the
proliferation, but certainly on intrahepatic, lymphatic and
hematogenous dissemination of HCC.
Therefore, our results are in line with recent publications from
our group and others, reporting a similar effect of CXCR4 on
disease dissemination in other tumour entities, such as non-small-
cell lung cancer (NSCLC), colorectal or breast cancer (Schimanski
et al, 2005). Furthermore, CXCR4 expression was found upregu-
lated in glioblastoma and its consecutive receptor inhibition was
followed by tumour cell arrest (Rubin et al, 2003). In osteo-
sarcoma, the level of CXCR4 expression was inversely correlated
with overall survival, but positively associated with detection of
metastasis (Larverdiere et al, 2004). Likewise, a grade 3 CXCR4
expression in our HCC patients was associated with a significantly
reduced 3-year-survival, due to hepatic failure following diffuse
intrahepatic HCC dissemination. The prolonged average survival
rate of our patients as compared to reported survival rates in
standard HCC patients resulted from a high rate of orthotopic liver
transplantations in our patient group. Nevertheless, the impact of a
strong CXCR4 expression on disease progression might depend on
the type and location of the primary carcinoma and most likely on
other parameters, which have not been defined yet. In line with
this theory, a strong CXCR4 expression was associated with
noninvasive gastric cancers and not with lymph node metastases
(Kwak et al, 2004).
CONCLUSION
Certain chemokines have been proposed to distinctly contribute to
tumour growth, dissemination and local immune scape (Balkwill
and Mantovani, 2001). Our in vitro and in vivo results are in line
with these data for human HCC. Strong expression of CXCR4 by
HCC was significantly associated with intrahepatic, nodal and
distant dissemination. Thus, CXCR4 apparently plays a relevant
role during HCC progression. Further efforts will be necessary to
evaluate the inhibition of dissemination by CXCR4 antagonists.
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